Biogen Inc BIIB:NASDAQ (Common Stock)

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
401.71 -28.57   -6.64%6,084,4061.9M
Market data is delayed by at least 20 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 4/24/2015

Latest News Headlines for Biogen Inc

Biogen Reports First Quarter 2015 Revenues of -3-

detailed below) 0.33 0.45 ----- ----- Non-GAAP earnings per share - Diluted $ 3.82 $ 2.47 ===== =====

Biogen Reports First Quarter 2015 Revenues of -2-

The Company's earnings conference call for the first quarter will be broadcast via the internet at 8:00 a.m. EDT on April 24, 2015, and will be accessible through the Investors section of Biogen's homepage, www.biogen.com. Supplemental information in the form of a slide presentation will also be accessible at the same location on the internet at the time of the conference call and will be subsequently available on the website for at least one month.

Biogen Reports First Quarter 2015 Revenues of $2.6 Billion

Multiple sclerosis portfolio gains share globally with ongoing TECFIDERA(R) rollout in Europe and launch of PLEGRIDY(R) Company advances research pipeline and development efforts in Alzheimer's disease, secondary progressive MS and neurological repair for MS

View more recent headlines

Peers Information HelpBIIB Biogen Inc vs. Peers

BIIB
Biogen Inc
18.34%
-3.34%
Johnson & Johnson
Pfizer Inc.
13.23%
Merck & Co., Inc.
1.43%
AbbVie Inc
0.96%
BIIB
Biogen Inc
0.00%
Johnson & Johnson
2.97%
Pfizer Inc.
3.18%
Merck & Co., Inc.
3.13%
AbbVie Inc
3.09%
-6.64%
BIIB
Biogen Inc
Johnson & Johnson
0.62%
-0.25%
Pfizer Inc.
Merck & Co., Inc.
0.16%
AbbVie Inc
2.83%
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Biogen Inc., formerly Biogen Idec Inc., is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company’s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. AVONEX is prescribed treatments for relapsing forms of multiple sclerosis (MS). AVONEX is a recombinant form of the interferon beta protein produced in the body in response to viral infection. TYSABRI is a monoclonal antibody approved in numerous countries as a monotherapy treatment for relapsing MS and to treat Crohn’s disease. The Company’s RITUXAN is a monoclonal antibody therapeutic used to treat non-Hodgkin’s lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia among others. FAMPYRA addresses the need of walking improvement in adult patients with MS who have walking disability and for the treatment of psoriasis.

https://www.biogen.com/

Loading...

collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open410.00
Previous Close401.71
Day High--
Day Low--
52 Week High3/20/2015 | 480.18
52 Week Low4/28/2014 | 275.3925
% Off 52 Week High(16.34)%
% Off 52 Week Low45.87%
Beta (5 Yr)1.0
Volatility Avg4/24/2015 | 33.80
10-Day Avg. Volume1,934,174
Market data is delayed by at least 20 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)3/31/2015 | 13.85
P/E Ratio3/31/2015 | 29.0
Market CapLarge Cap | 94.2B
Shares Outstanding234.61M
Float234.4M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Ex-Date--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short2.60M
Short Ratio--
Short % of Float1.11%
As of 4/15/2015